Mitochondrial calcium uniporter inhibition attenuates mouse bone marrow-derived mast cell degranulation induced by beta-1,3-glucan

Dang Van Cuong¹, Hyoung Kyu Kim¹,², Jubert Marquez¹, Nari Kim¹, Kyung Soo Ko¹, Byoung Doo Rhee¹, and Jin Han¹

¹National Research Laboratory for Mitochondrial Signaling, Department of Physiology, Department of Health Sciences and Technology, BK21 Project Team, College of Medicine, Cardiovascular and Metabolic Disease Center, Inje University, ²Department of Integrated Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea

INTRODUCTION

Mast cells are found in several tissues throughout the body, primarily in blood vessels, nerves, and organ systems that interact with the external environment. Bone marrow-derived mast cells express a variety of phenotypic features and are crucial in numerous biological functions [1]. Various stimuli activate mast cells in order to proceed with degranulation, a process during which secretory vesicles release specific secondary metabolites. Mast cell activation can be mediated by pathways that are either dependent or independent on high-affinity IgE receptor (FcεRI).

Multivalent antigen (allergen) may interact with its specific IgE antibody attached to the cell membrane via its FcεRI [2]. Mast cells can also be activated by non-immunological substances such as neuropeptides, basic compounds, complement components, and certain drugs [3]. Mast cell degranulation induced by immunological and non-immunological stimuli appear morphologically similar. However, the biochemical processes that lead to mediator release may differ. In FcεRI-dependent pathways, FcεRI phosphorylation induces exocytosis, which increases cytosolic calcium and induces degranulation. The concurrent activation of Ca²⁺ signaling by inositol-1,4,5-P₃ (IP₃)
and protein kinase C (PKC) signaling by diacylglycerol (DAG) interact synergistically to elicit mast cell degranulation [4]. In FcεRI-independent pathways, mast cells may be activated by numerous stimuli including basic compounds (compound 48/80, mastoparan, and polymyxin B), peptides (melittin, substance P, calcitonin gene-related peptide, somatostatin, and neurotensin), and cytokines (IL-1, IL-3, GM-CSF, platelet factor 4, and IL-8) [1].

Beta-1,3-glucan (BG), which is found in the cell wall of many fungi, has been reported to modulate immunity [5]. It was isolated from S. cerevisiae and was originally reported as zymosan, a kind of β-1,3-glucan, in 1959 by Benacerraf, and demonstrated that it produced hyperplasia and hyper functionality in fixed tissue macrophages [6]. Many subsequent studies have shown that zymosans, particularly BG, increase the function of macrophages, neutrophils, basophils, mast cells, and other immunocytes [7]. Depending on the size and the origin, the molecular effects of BG are diverse. High molecular weight BGs appear to directly activate leukocytes and stimulate phagocytic, cytotoxic, and anti-microbial activities, leading to the production of many pro-inflammatory mediators, cytokines, and chemokines (IL-8, IL-1β, IL-6, and TNFα) [5]. Low molecular weight BGs are reported to induce the release of IL-8, IL-6, and nuclear transcription factors such as NF-κB and NF IL-6 [8]. BG stimulates and activates mast cells by binding with BG receptor on the surface of macrophages. Stimulation of 1,3-BG-receptors results in Ca²⁺ influx through receptor-operated channels. [9,10]. An increase in intracellular Ca²⁺ ([Ca²⁺]i) is necessary for BG-induced mast cell exocytosis, but whether this Ca²⁺ is derived from extracellular or intracellular pools is still controversial [11].

Mitochondria are key subcellular organelles which regulate the life and death of cells via producing ATP and triggering apoptosis signals. Beside, mitochondria regulate intracellular Ca²⁺ homeostasis by uptake and release of intracellular Ca²⁺ responded to various biological processes. Because mast cell activation and degranulation are highly ATP and Ca²⁺ dependent process, many studies demonstrated the important role of mitochondria in mast cell degranulation [12-17]. However, those findings were mainly found in FcεRI- mediated degranulation. The mechanisms underlying BG-induced degranulation and the mitochondrial role in this process are not well known yet.

The present study aimed to investigate the role of cytosolic and mitochondrial calcium in BG-induced mast cell degranulation. Our results provide important evidence for the role of mitochondrial Ca²⁺ uniporter in the BG mediated by mast cell degranulation.

**METHODS**

**Preparation of bone marrow-derived mast cells**

Eight-week-old C57BL mice were used for all experiments. Bone marrow-derived mast cells (BMBCs) were collected and cultured in Iscove’s modified Dulbecco’s medium (IMDM, Thermo Fisher, Waltham, USA ) supplemented with 15% fetal bovine serum (FBS, Thermo Fisher, Waltham, USA), 15 μM thiglycyrkol, 2 mM L-glutamine, stem cell factor (SCF; 50 ng/ml), and IL-3 (30 ng/ml); cells were incubated at 37°C, 95% O₂, and 5% CO₂. Media were changed every week. After 4 weeks, cells were used for experiments. All animal studies were approved by the Inje Medical University Animal Care and Use Committee.

**Drugs and solutions**

Normal Tyrode’s solution (NT) contained (in mM): 143.0 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 0.5 mM MgCl₂, 5.5 mM glucose, and 5.0 mM HEPES (pH 7.4). Fluorescent probes were supplied by Molecular Probes (Eugene, Oregon, USA). The tryptase release kit was purchased from Chemicon (CA, USA). FITC anti-mouse FcεRI, PE anti-mouse CD117, and isotype controls were supplied by eBioscience (CA, USA). All other reagents were obtained from Sigma (St. Louis, MO, USA).

**Mast cell confirmation**

BMBCs were cultured as described above and collected every week to check the development of the mast cell population. Mast cells were confirmed by toluidine blue staining, flow cytometry analysis, and laser scanning confocal microscopy. For toluidine blue staining, cells were stained with toluidine blue for 10 min at room temperature, and then visualized under a light microscope connected to a camera. For flow cytometry analysis, cells were stained with phycoerythrin (PE) anti-mouse FcεRIa and fluorescein isothiocyanate (FITC) anti-mouse CD117 (c-Kit). Cells were then subjected to flow cytometry using the CellQuestPro with FL1 filter for FITC anti-mouse CD117 and FL2 filter for PE anti-mouse FcεRI [18]. For laser scanning confocal microscopy, cells were stained with FITC anti-mouse CD117, PE anti-mouse FcεRI, or both probes. Cells were then visualized using laser scanning confocal microscopy with excitation/emission filters for visualizing FITC anti-mouse CD117 (488/505 nm) and PE anti-mouse FcεRI (514/560 nm).

**BMMC stimulation**

BMMC degranulation was stimulated with different types of stimulators including beta-1,3-glucan (BG, 0.1 mg/ml), peptidoglycan from Staphylococcus aureus (PGN, 100 μg/ml), or calcium ionophore A23187 (10 μM) in normal Tyrode’s solution to compare the pathway specific degranulation responses in mast cell. BG, PGN or A23187 stimulates mast cell through BG-receptors [19], TLR-2 pathway [20] or direct increase of intracellular Ca²⁺ [21], respectively. To test the role of the mitochondrial calcium uniporter (MCU), we used ruthenium red.
(RuR, 5 μM) as a selective MCU inhibitor. Calcium-free solution was prepared by the addition of 1 mM EGTA.

**Tryptase release measurement**

Tryptase is a tetrameric serine proteinase that has emerged as a major component of mast cell granules. Tryptase was measured using a kit according to the manufacturer's instructions. Briefly, BMMCs were suspended in Tyrode’s solution and stimulated as described above. After the desired period of activation, the samples were centrifuged at 800 × g to separate supernatant and pellet. The pellet was then sonicated and centrifuged to collect lysate. Both supernatant and lysate were used to evaluate tryptase concentration. Tryptase concentration was determined spectrophotometrically (EL-800, BioTek Instruments) at 405 nm. Mast cell degranulation was calculated as percentage of released tryptase relative to the total tryptase using the following equation:

\[
\text{Degranulation} = \frac{\text{Tryptase}_{\text{sup}} \times 100}{(\text{Tryptase}_{\text{sup}} + \text{Tryptase}_{\text{lysate}})}.
\]

**Dynamic measurements of cytosolic and mitochondrial calcium and membrane potential**

To evaluate \([\text{Ca}^{2+}]_i\), BMMCs were stained for 30 min with 5 μM Fluo4-AM, a specific cell-permeant probe that binds to cytosolic \(\text{Ca}^{2+}\). To measure mitochondrial \(\text{Ca}^{2+}\), BMMCs were incubated with 5 μM Rhod2-AM, a selective indicator for mitochondrial \(\text{Ca}^{2+}\), for 1 hour at 4°C, and then briefly incubated for 5 min at room temperature.

Mitochondrial membrane potential (ΔΨm) was measured using tetramethylrhodamine ethyl ester perchlorate (TMRE). BMMCs were incubated with 2 μM TMRE for 15 min at room temperature. After staining, BMMCs were washed twice with NT buffer, and fluorescence was imaged using a laser scanning confocal microscope.

**Monitoring vesicle release during mast cell degranulation**

To monitor vesicle degranulation, BMMCs were stained with LysoTracker Red DND99 (LTR) [22]. We measured the reduction in total cellular fluorescence intensity and monitored vesicle movement out of the cell membrane. We confirmed the decline of LTR during degranulation by comparing with tryptase release.

**Fluorescence imaging by laser scanning confocal microscopy**

BMMCs stained with fluorescent probes were placed on a poly-L-lysine-coated cover glass that was placed inside a perfusion chamber, and subjected to experimental protocols. Fluorescence was acquired using a confocal laser scanning microscope (inverted Axiovert 200M, Zeiss, Jena, Germany) at 200× and 400× magnification. Data were analyzed with LSM5 10META software (Zeiss, Jena, Germany). Fluo4-AM, Rhod2-AM, and TMRE were visualized with suitable filter sets at excitation/emission wavelengths at 488 nm/520 nm, 550 nm/580 nm, 514/560 nm, respectively.

**Statistical analysis**

Data were analyzed using Microcal Origin v. 6.0 software. All data are presented as mean±SE. A p-value<0.05 was considered to be statistically significant.
RESULTS

Mast cell confirmation from 4-week-old bone marrow-derived cells

Bone marrow-derived cells cultured for 4 weeks showed a high percentage of mast cells. Toluidine blue staining confirmed that more than 98±1% of the total population were BMMCs (Fig. 1A, B). Flow cytometry analysis indicated that 97±0.6% and 98.3±0.4% of cells were bound with anti-FcεRI and anti-c-Kit probes, respectively (Fig. 1C). Images obtained from laser scanning confocal microscopy also indicated that the samples contained a high percentage of mast cells, with more than 98% cells co-localizing FcεRI and c-Kit (Fig. 1D).

Degranulation increased cytosolic and mitochondrial calcium

BG induced increases in both cytosolic and mitochondrial calcium ([Ca^{2+}]_{c} and [Ca^{2+}]_{m}, respectively) (Fig. 2A). After 30 min of BG treatment, [Ca^{2+}]_{m} increased to 293±61.5% and then declined to 195.5±22.9% after washout (50 min). The [Ca^{2+}]_{c}, and mitochondrial membrane potential (ΔΨm) during BG stimulation of mast cell degranulation. (C) Normalized changes in mitochondrial Ca^{2+} levels monitored in BMMCs stained with Rhod2-AM. (D) Normalized changes in cytosolic Ca^{2+} levels monitored in BMMCs stained with Fluo4-AM. (E) Normalized changes in ΔΨm monitored in TMRE-stained BMMCs. a, b, and c represent 5, 30, and 50 min, respectively. (F) Normalized comparison of mitochondrial Ca^{2+} elevation induced by BG or PGN treatment. (C–E) *p<0.05 vs. time point a, †p<0.05 vs. time point b. (F) *p<0.05 vs. Control.
values for the same intervals were 147.1±11.2% and 134.5±8.9%, respectively. Analysis of TMRE-associated mitochondrial membrane potential (ΔΨm) showed that BG treatment increased TMRE intensity to 155.7±9.7% (at 30 min), which then declined to 58.4±11.1% (at 50 min washout) (Fig. 2B-E). PGN also significantly increased $[Ca^{2+}]_{m}$ to 159.9±12.8% of that in control cells (Fig. 2F).

**BG induced BMMC degranulation**

BMMC degranulation was evaluated by both tryptase release measurement and LysoTracker Red DND99 (LTR) probe methods. We visualized cells with confocal microscopy to observe vesicle movement after incubating BMMC with BG (Fig. 3A). We observed two phases of exocytosis within the time frame of our experiments. The total LTR levels in mast cells decreased after a few minutes (<20 min), and again declined after 30 min since the start of BG treatment (Fig. 3B, C). We selected narrow areas at the cell periphery near the cell membrane to detect vesicle movement. Two phases of degranulation was illustrated in left panel of Fig. 3D. Fluorescence images showed that LTR-stained vesicles in the cytoplasm were still present after the BG-induced early phase of exocytosis of membrane proximal vesicles (Fig. 3D right).

**Inhibition of the mitochondrial calcium uniporter attenuated degranulation**

BG treatment of BMMCs in the absence of extracellular Ca$^{2+}$ (by adding 1 mM EGTA to the medium) resulted in less reduction of LTR fluorescence compared with that in normal Tyrode's medium (1.8 mM CaCl$_2$) (Fig. 3E). The second degranulation phase (after 30 min) was blocked by the presence of 5 μM RuR (Fig. 3B and E).

The addition of 5 μM RuR inhibited tryptase release induced by A23187, PGC, and BG in the presence of normal extracellular Ca$^{2+}$. RuR had a weaker effect on A23187-induced degranulation than on PGN- and BG-induced degranulation. The percentage of degranulation induced by A23187, PGN, and BG were 70.6, 59.5, and 64.3%, respectively, in the absence of RuR and 51.5, 35.5, and 29.3%, respectively, in the presence of RuR (Fig. 4). A23187-, PGN-, and BG-induced degranulation was significantly suppressed in the absence of extracellular Ca$^{2+}$ (Fig. 4).

**DISCUSSION**

This study demonstrated that the mitochondrial calcium uniporter is an important regulator of Ca$^{2+}$-dependent BG-induced mast cell degranulation. BGs are natural polysaccharides which are contained in the cell wall of yeast, fungi and seaweed. Various BGs can be classified according to molecular characteristics such as molecular mass, solubility, viscosity, and three-dimensional configuration. BG is widely used in various clinical applications including in DNA damage protection [23], antioxidative therapy [24], anti-cancer [25] and immune stimulation [19]. Among these clinical applications, the role of BG in mast cell stimulation and degranulation has been extensively studied due to its importance in cytokine-mediated immune response [26-30]. Several mechanisms and components involved in mast cell degranulation have been identified, including the molecular receptor, signaling pathways, localization modulator, candidate ligands, and Ca$^{2+}$ regulation [4,10,31-34]. Cellular recognition of BG is suggested by the characterization of four types of BG receptors: scavenger receptor, CR3, lactosyl ceramide, and dectin-1 [19]. A recent study reported that dectin-1 was almost exclusively responsible for the BG-dependent nonopsonic recognition of zymosan by primary macrophages [34].

Intracellular and/or extracellular Ca$^{2+}$ pools are determining factors of mast cell degranulation [12,15,21]. During BG-mediated activation of a macrophage cell line, stimulation of 1,3-BG receptors via zymosan enhanced Ca$^{2+}$ influx through PKC delta and receptor-operated Ca$^{2+}$ channels without an increase in IP3 production [9,10]. Consistent with the findings of a previous study regarding macrophages, our results showed that BG treatment gradually increased [Ca$^{2+}$]$_{i}$ in BMMCs (Fig. 2B and D).

Mitochondria are important regulators of mast cell functions including energy production [35], apoptosis [36-38], Ca$^{2+}$ mobility [39], and degranulation [40-42]. Cross talk between mitochondria and cytosolic Ca$^{2+}$ regulation has been suggested as an important mechanism regulating degranulation [12-17]. Suzuki et al. suggested that the mitochondrial permeability transition pore (mPTP) is the fast-releasing Ca$^{2+}$ channel [13] and MCU as a Ca$^{2+}$ uptake channel. At low Ca$^{2+}$ concentrations (0.1 μM), IP3-sensitive storage primarily uptake Ca$^{2+}$, but at higher Ca$^{2+}$ concentrations (>1 μM), Ca$^{2+}$ uptake is primarily into mitochondria via MCU [15,43]. Inhibition of mitochondrial metabolism [13,39] or targeted knockdown of MCU [17]...
significantly reduced FcεRI-mediated mast cell degranulation. Mitochondrial membrane potential is an important factor regulating FcεRI-mediated mast cell degranulation [13]. Under normal extracellular Ca^{2+} levels, a mitochondrial inhibitor and a mitochondrial uncoupler inhibit IgE-induced degranulation. In contrast, antimycin A and FCCP enhance degranulation in the absence of extracellular Ca^{2+}. IgE-mediated stimulation did not induce ΔΨm depolarization during degranulation [13].

There was limited evidence for the role of mitochondria in BG-dependent mast cell activation. We demonstrated that BG increased both cytosolic and mitochondrial Ca^{2+} levels (Fig. 2). In addition, we observed that BG rapidly induced an approximately two-fold increase in ΔΨm (hyperpolarization), before gradually declining (depolarization). These results suggest that mitochondrial ΔΨm and [Ca^{2+}]_{m} are involved in BG-induced BMMC degranulation.

To understand the functional role of mitochondrial Ca^{2+} during BMMC degranulation, we used RuR to block MCU activity and observed an alteration in degranulation rate. BG treatment induces vesicle release in two phases. The first degranulation phase occurred within seconds after treatment and continued until 20 min after the start of degranulation. During this period, approximately 20–30% of all vesicles were released. The second degranulation phase occurred within 20–40 min after the start of degranulation, when approximately 70% of all vesicles were released. Both degranulation phases were inhibited in the absence of extracellular Ca^{2+}, when approximately 70% of all vesicles were released. The second phase occurred within seconds after treatment and continued

ACKNOWLEDGMENTS

This study was supported by a grant from the Priority Research Centers Program and Basic Science Research Program through the National Research Foundation of Korea (NRF), Funded by the Ministry of Education, Science and Technology (2010-0020224, 2012R1A2A1A03007595 and NRF-2015R1D1A1A01057937), Republic of Korea.

CONFLICT OF INTEREST

None.

REFERENCES

1. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033-1079.
2. Wedemeyer J, Galli SJ. Mast cells and basophils in acquired immunity. Br Med Bull. 2000;56:936-955.
MCU inhibition regulates mast cell degranulation

3. Kaluca M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. *Immunology*. 2008;123:398-410.

4. Roth K, Chen WM, Lin TJ. Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation. *Arch Immunol Ther Exp (Warsz)*. 2008;56:385-399.

5. Williams D, Mueller A, Browder W. Glucan-based macrophage stimulators. *Clin Immunother*. 1996;5:392-399.

6. Benacerraf B, Thorbecke GJ, Jacoby D. Effect of zymosan on endotoxin toxicity in mice. *Proc Soc Exp Biol Med*. 1959;100:796-799.

7. Williams JD, Topley N, Alobaidi HM, Harber MJ. Activation of human polymorphonuclear leucocytes by particulate zymosan is related to both its major carbohydrate components: glucan and mannan. *Immunology*. 1986;58:117-124.

8. Adams DS, Petro SC, Petro JB, Nathans R, Mackin WM, Wakshull E. PGG-Glucan activates NF-kappaB-like and NF-IL-6-like transcription factor complexes in a murine monocyctic cell line. *J Leukoc Biol*. 1997;62:865-873.

9. Zhang GH, Helmke RJ, Mörk AC, Martinez JR. Regulation of cytosolic free Ca\(^{2+}\) in cultured rat alveolar macrophages (NR8383). *J Leukoc Biol*. 1997;62:341-348.

10. Mörk AC, Sun X, Liu X, Rodriguez D, Martinez JR, Castro R, Zhang GH. Regulation of (1-3)-beta-glucan-stimulated Ca\(^{2+}\) influx by protein kinase C in NR8383 alveolar macrophages. *J Cell Biochem*. 2000;78:131-140.

11. Sengelov H, Kjeldsen L, Borregaard N. Control of exocytosis in early neutrophil activation. *J Immunol*. 1993;150:1535-1543.

12. Mohr FC, Fieweitl C. The effect of mitochondrial inhibitors on calcium homeostasis in tumor mast cells. *Am J Physiol*. 1990;258:C217-226.

13. Suzuki Y, Yoshimaru T, Inoue T, Ra C. Mitochondrial Ca\(^{2+}\) influx is a critical determinant of the Ca\(^{2+}\) dependence of mast cell degranulation. *J Leukoc Biol*. 2006;79:508-518.

14. Suzuki Y, Yoshimaru T, Inoue T, Nunomura S, Ra C. The high-affinity immunoglobulin E receptor (FcepsilonRI) regulates mitochondrial calcium uptake and a dihydropyridine receptor-mediated calcium influx in mast cells. Role of the FcepsilonRIIBeta chain immunoreceptor tyrosine-based activation motif Biochem Pharmacol. 2008;75:1492-1503.

15. Ma HT, Beaven MA. Regulation of Ca\(^{2+}\) signaling with particular focus on mast cells. *Crit Rev Immunol*. 2009;29:155-186.

16. Inoue T, Suzuki Y, Ra C. Epigallocatechin-3-gallate inhibits mast cell degranulation, leukotriene C\(_4\) secretion, and calcium influx via mitochondrial calcium dysfunction. *Free Radic Biol Med*. 2010;49:632-640.

17. Furuno T, Shinkai N, Inoh Y, Nakashii M. Impaired expression of the mitochondrial calcium uniporter suppresses mast cell degranulation. *Mol Cell Biochem*. 2015;410:215-221.

18. Gurish MF, Friend DS, Webster M, Ghildyal N, Nicodemus CF, Stevens RL. Mouse mast cells that possess segmented/multi-lobular nuclei. *Blood*. 1997;90:382-390.

19. Akramienie D, Kondrotas A, Diaziaetiene J, Kevelaitis E. Effects of beta-glucans on the immune system. *Medicina (Kaunas)*. 2007;43:597-606.

20. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, Ogawa H. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. *J Clin Invest*. 2002;109:1351-1359.

21. Hosokawa J, Suzuki K, Nakagomi D, Tamachi T, Takatori H, Suto A, Nakajima H. Role of calcium ionophore A23187-induced activation of IkappaB kinase 2 in mast cells. *Int Arch Allergy Immunol*. 2013;161 Suppl 2:37-43.

22. Mizuno K, Tolmachova T, Ushakov DS, Romao M, Abrik M, Ferenczi MA, Ra C, Ogawa H. Differential responses of mast cell Toll-like receptors 2 and 4 in mast cells. *J Immunol*. 2007;43:597-606.

23. Slamenova D, Labaj J, Krizková L, Kogan G, Sandula J, Bresgen N, Eckl P. Protective effects of fungal (1→3)-beta-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cells. *Cancer Lett*. 2003;198:153-160.

24. Krizková L, Duracková Z, Sandula J, Slamenova D, Sasinková V, Sivonová M, Krajcovic J. Fungal beta-(1-3)-D-glucan derivatives exhibit high antioxidative and antimitagenic activity in vitro. *Anticancer Res*. 2003;23:2751-2756.

25. Nasrollahi Z, Mohammad SR, Mollarazi E, Yadegari MH, Hassan ZM, Talaei F, Dinarnard R, Akbari H, Atyabi F. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study. *J Control Release*. 2015;202:49-56.

26. Zanoni I, Granucci F. Regulation and dysregulation of innate immunity by NFAT signaling downstream of pattern recognition receptors (PRRs). *Eur J Immunol*. 2012;42:1924-1931.

27. Sakurai A, Yamaguchi N, Sonoyama K. Cell Wall Polysaccharides of Candida albicans Induce Mast Cell Degranulation in the Gut. *Biosci Microbiota Food Health*. 2012;31:67-70.

28. Kimura Y, Chihara K, Honjoh C, Susa K, Atayaki F, Fujieda S, Sada K. Dectin-1-mediated signaling leads to characteristic gene expressions and cytokine secretion via spleen tyrosine kinase (Syk) in rat mast cells. *J Biol Chem*. 2014;289:31565-31575.

29. Cleave JA, Kelly GE, Husband AJ. The effect of molecular weight and beta-1,6-linkages on priming of macrophage function in mice by (1,3)-beta-D-glucan. *Immunol Cell Biol*. 1999;77:395-403.

30. Kolaczkowska E, Seljeld R, Płytcz B. Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast-cell-deficient WBB6F1 mice. *J Leukoc Biol*. 2001;69:33-42.

31. Marshall JS, Stead RH, McSharry C, Nielsen L, Bienenstock J. The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. *J Immunol*. 1990;144:1886-1892.

32. Dvorak AM, Galli SJ, Schulman ES, Lichtenstein LM, Dvorak HF. Basophil and mast cell degranulation: ultrastructural analysis of mechanisms of mediator release. *Fed Proc*. 1983;42:2510-2515.

33. Nishida K, Yamasaki S, Ito Y, Kabu K, Hattori K, Tsuchiya Y. The mechanism of action of nerve growth factor. *J Immunol*. 1983;131:2510-2515.

34. Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Gordon S. The mechanism of action of nerve growth factor. *J Immunol*. 1990;144:1886-1892.

35. Weatherly LM, Shim J, Hashmi HN, Kennedy RH, Hess ST, Gosse JA. Antimicrobial agent triclosan is a proton ionophore uncoupler of mitochondria in living rat and human mast cells and in primary human keratinocytes. *J Appl Toxicol*. 2015. doi: 10.1002/jat.3209. [Epub ahead of print]
36. Yoshimaru T, Suzuki Y, Inoue T, Nishida S, Ra C. Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products. Biochim Biophys Acta. 2008;1783:2332-2343.

37. Inoue T, Suzuki Y, Mizuno K, Nakata K, Yoshimaru T, Ra C. SHP-1 exhibits a pro-apoptotic function in antigen-stimulated mast cells: positive regulation of mitochondrial death pathways and negative regulation of survival signaling pathways. Mol Immunol. 2009;47:222-232.

38. Suzuki Y, Yoshimaru T, Inoue T, Ra C. Ca\textsuperscript{2+} L-type Ca\textsuperscript{2+} channel protects mast cells against activation-induced cell death by preventing mitochondrial integrity disruption. Mol Immunol. 2009;46:2370-2380.

39. Takekawa M, Furuno T, Hirashima N, Nakanishi M. Mitochondria take up Ca\textsuperscript{2+} in two steps dependently on store-operated Ca\textsuperscript{2+} entry in mast cells. Biol Pharm Bull. 2012;35:1354-1360.

40. Erlich TH, Yagil Z, Kay G, Peretz A, Migalovich-Sheikhet F, Tshori S, Nechushtan H, Levi-Schaffer F, Saada A, Razin E. Mitochondrial STAT3 plays a major role in IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol. 2014;134:460-469.

41. Zhang B, Weng Z, Sismanopoulos N, Asadi S, Theoharides TC. Human mast cell degranulation and preformed TNF secretion require mitochondrial translocation to exocytosis sites: relevance to atopic dermatitis. J Allergy Clin Immunol. 2011;127:1522-1531.e8.

42. Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One. 2012;7:e49767.

43. Chang KT, Schwarz TL. The mechanism of Ca\textsuperscript{2+}-dependent regulation of kinesin-mediated mitochondrial motility. Cell. 2009;136:163-174.

44. Chang KT, Niescer RF, Min KT. Mitochondrial matrix Ca\textsuperscript{2+} as an intrinsic signal regulating mitochondrial motility in axons. Proc Natl Acad Sci U S A. 2011;108:15456-15461.

45. Niescer RF, Chang KT, Min KT. Miro, MCU, and calcium: bridging our understanding of mitochondrial movement in axons. Front Cell Neurosci. 2013;7:148.

46. Vetticka V, Vettickova J, β(1-3)-D-glucan affects adipogenesis, wound healing and inflammation. Orient Pharm Exp Med. 2011;11:169-175.